Hello, good morning. My name is Julio Chavez. I'm from the Moffitt Cancer Center in Tampa, Florida. It was a randomized clinical trial comparing a bi-specific antibody called mosinetuzumab plus an ADC antibody drug conjugate called polatuzumab versus polatuzumab and rituximab. So the idea was to assess the response of this combination in patients with high risk diffuse laryngocellin format that had relapsed at least after one line of therapy. So the study enrolled 80 patients, 40 patients each arm, and we saw significantly higher response rates in the mosinetuzumab and polatuzumab arm in comparison to polatuzumab and rituximab alone. Also, the duration of response, the duration of complete response was better as well as the progression of free survival. So this study actually responded several questions. One of the questions was, first, can mosinetuzumab be given safely as a fully outpatient regimen? It was. As opposed to prior mosinetuzumab studies, the mosin administration was succutaneous, and that led to lower cytokine release syndrome, which is a common toxicity with bi-specific antibodies, and also lower or essentially non-existent neurotoxicity. So about 10% of patients had any type of toxicity. So it was fully outpatient. That was kind of like one of the more remarkable things other than the efficacy. So I think this is a regimen that should be considered for patients with aggressive micellium format that don't have access to CAR-T now that we have approval for CAR-T in the second line, but many patients cannot access because of distance, logistics, and hospitalization. Still community doctors are not very comfortable giving a bi-specific because of the high rates of CRS that I still use, even though the majority of our low-grade CRS. But in this case, we have very low rates, like a 10%, 12%. So I think that was kind of like the most remarkable.
HealthTree • January 21, 2025